Related Experiment Video
Updated: Jul 6, 2026
06:12
Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
Published on: March 3, 2023
[Varenicline--a new chance for smokers?]
Maciej Lukasz Goniewicz1, Bartosz Koszowski, Jan Czogała
1Zakład Chemii Ogólnej i Nieorganicznej, Katedry Chemii Ogólnej i Analitycznej, Slaskiego Uniwersytetu Medycznego w Katowicach. mgoniewicz@wp.pl
Przeglad Lekarski
|April 16, 2008
Summary
Varenicline (Champix) is a highly effective smoking cessation aid, showing a 40% success rate. This drug offers a dual mechanism of action, acting as both an agonist and antagonist to nicotinic receptors, making it a promising option for smokers seeking to quit.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Development
Context:
- Smoking cessation remains a significant public health challenge.
- Pharmacological interventions are crucial for supporting individuals attempting to quit smoking.
- Varenicline (Champix) has recently been introduced to the Polish market.
Purpose:
- To critically review current information on varenicline's pharmacology and pharmacokinetics.
- To evaluate the safety and economic aspects of varenicline therapy.
- To assess varenicline's efficacy in smoking cessation.
Summary:
- Varenicline exhibits a dual mechanism as a partial agonist and antagonist at alpha4beta2 nicotinic receptors.
- This dual action facilitates smoking cessation by managing nicotine cravings and withdrawal symptoms.
- The drug demonstrates a high relative effectiveness, with approximately 40% success rates in cessation attempts.
Impact:
- Varenicline represents a significant advancement in smoking cessation pharmacotherapy.
- Its unique pharmacological profile and demonstrated effectiveness offer a promising, safe, and potentially cost-effective solution for smokers.
- Successful therapy completion yields substantial health and economic benefits outweighing initial treatment costs.
Related Concept Videos
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:29Stimulants
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...